Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16136
Title: Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era
Authors: Jalali, Azim;Ha, Francis J;Chong, Geoff;Grigg, Andrew P;Mckendrick, Joe;Schwarer, Anthony P;Doig, Rowan;Hamid, Anis;Hawkes, Eliza A
Issue Date: Apr-2016
EDate: 2016-04
Citation: Annals of Hematology 2016; 95(5): 809-816
Abstract: Approximately 560 new cases of Hodgkin lymphoma (HL) are diagnosed annually in Australia. Standard first-line therapy is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). It is unknown how survival outcomes in patients receiving ABVD in current clinical practice, with routine positron emission tomography (PET) imaging and modern supportive measures, compare with results from published trials. This is a retrospective multi-centre study of patients with previously untreated HL between November 1999 and December 2014 receiving ABVD induction. Baseline characteristics, treatment details, toxicity and outcome data were collected from hospital records. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), response to treatment and toxicity. One hundred and eighty-nine eligible patients were identified. Median age was 32 years (range 17-79). Nodular-sclerosing HL was the most common subtype (78 %), 44 % had B symptoms and 11 % had marrow involvement. Median number of cycles of ABVD administered was 6 (range 3-8). Eighteen patients (11 %) had dose delay, 21 (13 %) had dose reductions and 11 (8 %) had both. The ORR, defined predominantly by PET scan, was 96 % (CR 89 %). Five-year OS and PFS were 93 and 84 %, respectively in early disease (stage I-IIA) and 89 and 63 % in advanced disease (stage IIB, III and IV). No poor prognostic factors were identified on multivariate testing. The most common grade 3/4 toxicity was neutropenia (53 %). Our study confirms the excellent prognosis and manageable toxicity in HL patients receiving ABVD in phase III studies are reflected in patients treated in routine clinical practice in the modern era.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16136
DOI: 10.1007/s00277-016-2611
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/26878861
Type: Journal Article
Subjects: ABVD
Chemotherapy
Hodgkin lymphoma
Survival
Toxicity
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.